Bardet-Biedl Syndrome 4 in Early Diagnosis and Prognosis of Breast Cancer

Abstract

Zhang et al.: Bardet-Biedl Syndrome 4 in Breast CancerBardet-Biedl syndrome 4 is the key protein to control cilia formation. In this study, bioinformatics method was used to screen the core genes related to the prognosis of breast cancer by analyzing the gene chip data of gene expression omnibus and the cancer genome atlas database, so as to provide a new candidate target for the treatment of breast cancer. Data were downloaded from the cancer genome atlas, gene expression omnibus to evaluate Bardet-Biedl syndrome 4 expression levels in breast cancer. Differentially expressed genes were screened by R package. Gene ontology and Kyoto encyclopedia of Genes and Genomes pathway enrichment analysis was used to explore the biological functions of differentially expressed genes. The correlation of differentially expressed genes used was, "corrplot" for visual analysis. The proteinprotein interaction relationship was constructed based on search tool for the retrieval of interacting genes/ proteins database and Cytoscape software and the key genes were obtained by module analysis with Cytoscape software molecular complex detection plugin and the prognostic value and survival of Bardet-Biedl syndrome 4 were evaluated by R package. Finally, the correlation between Bardet-Biedl syndrome 4 and clinicopathological parameters was also visualized by R package. These differentially expressed genes were mainly involved in response to peptide hormone, nuclear division, hormone secretion and transport and extracellular matrix. Genes were mainly involved in the Kyoto encyclopedia of genes and genomes pathway called Interleukin-17 signaling pathway. Bardet-Biedl syndrome 4 levels were found to be down regulated in breast cancer tissues compared with normal tissues. Survival analysis showed that low Bardet-Biedl syndrome 4 expression was associated with poor prognosis. These results were verified in clinical specimens, where in the Bardet-Biedl syndrome 4 protein levels were significantly down regulated in breast cancer tissues compared with non-breast cancer tissues. This study confirmed that Bardet-Biedl syndrome 4 can be used as an independent prognostic factor for the prognosis of breast cancer, which provides a basis for exploring a new target for the treatment of breast cancer.

Whole transcriptome analysis reveals non-coding RNA's competing endogenous gene pairs as novel form of motifs in serous ovarian cancer

“…The overexpression of PRC1 also indicates a poor prognosis [39]. Moreover, BBS4 has been observed down-regulated in breast cancer and indicates a shorter survival time [40]. Collectively, these findings suggest that circHUNK play potential roles in the downstream disturbance of cell division in SOV via competing endogenous RNA mechanisms (Fig.…”

“…Wang et al found that lncHCP5/miR-525-5p/PRC1 crosstalk might promote malignant behaviors of ovarian cancer cells and the silencing of lncRNA HCP5 impeded growth and metastasis of tumour in mice [38]. BBS4 was differentially expressed and downregulated in breast cancer and it was associated with poor prognosis [40]. Collectively, these findings inferred that the circHUNK in this cceGP might be associated with the regulation of gynecologic cancer and might be a potential target for anticancer drugs.…”

Circular RNA’s competing endogenous gene pair as motif in serous ovarian cancer

“…The overexpression of PRC1 also indicates a poor prognosis[42]. Moreover, BBS4 has been observed down-regulated in breast cancer and indicates a shorter survival time [43]. Collectively, these findings suggest that circHUNK play potential roles in the downstream disturbance of cell division in SOV via competing endogenous RNA mechanisms ( Figure 6I ).…”

“…Wang et al found that lncHCP5/miR-525–5p/ PRC1 crosstalk might promote malignant behaviors of ovarian cancer cells and the silencing of lncRNA HCP5 impeded growth and metastasis of tumour in mice [41]. BBS4 was differentially expressed and downregulated in breast cancer and it was associated with poor prognosis [43]. Collectively, these findings inferred that the circHUNK in this cceGP might be associated with the regulation of gynecologic cancer and might be a potential target for anticancer drugs.…”

Integrated analysis of -omic landscapes in breast cancer subtypes

“…Finally, the expression profiles of the ESR1 signature (spot S, Pearson correlation coefficient: 0.24-0.82, top correlated genes: SCUBE2, ESR1, ABCC8, RALGPS2, APH1B, BBS4, MYB, GALNT10, LMX1B, HHAT, [86][87][88][89][90] Supplementary Table S24 in Supplementary_Tables_S17-S24.xlsx file of "Extended data", see Data and software availability) were significantly downregulated in Lum B, HER2E, basal, and normal-like cancers, while were significantly upregulated in the Lum A subtype. In addition, the methylation profiles in the basal subtype were significantly increased compared to the true normal tissue.…”